Znanstveni rad - Pregledni rad
Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
Clinical Obesity, (2021), 1; 12439. https://doi.org/10.1111/cob.12439

Belančić, Andrej; Kresović, Andrea; Troskot Dijan, Marija

Povezani objekti
COVID-19 | Virtualna zbirka
Citirajte ovaj rad

Belančić, A., Kresović, A. i Troskot Dijan, M. (2021). Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?. Clinical Obesity, (1), 6. doi: 10.1111/cob.12439

Belančić, Andrej, et al. "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?." Clinical Obesity, br. 1, 2021, str. 6. https://doi.org/10.1111/cob.12439

Belančić, Andrej, Andrea Kresović i Marija Troskot Dijan. "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?." Clinical Obesity br. 1 (2021): 6. https://doi.org/10.1111/cob.12439

Belančić, A., Kresović, A. i Troskot Dijan, M. (2021) 'Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?', Clinical Obesity, (1), str. 6. doi: 10.1111/cob.12439

Belančić A, Kresović A, Troskot Dijan M. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?. Clinical Obesity [Internet]. 10.01.2021. [pristupljeno 11.07.2024.];(1):6. doi: 10.1111/cob.12439

A. Belančić, A. Kresović i M. Troskot Dijan, "Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?", Clinical Obesity, br. 1, str. 6, Siječanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:347912. [Citirano: 11.07.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.